Zai Lab Limited (FRA:1ZL)

Germany flag Germany · Delayed Price · Currency is EUR
16.80
+0.30 (1.82%)
Last updated: Dec 5, 2025, 8:10 AM CET
-40.43%
Market Cap 1.86B
Revenue (ttm) 376.40M
Net Income (ttm) -176.27M
Shares Out n/a
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 11
Open 16.80
Previous Close 16.50
Day's Range 16.80 - 16.80
52-Week Range 16.40 - 38.20
Beta n/a
RSI 31.16
Earnings Date Feb 27, 2026

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 1,869
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1ZL
Full Company Profile

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.